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Abstract
Background: Shigellosis causes diarrheal disease in humans from both developed and developing
countries, and multi-drug resistance is an emerging problem. The objective of this study is to
present a unified approach that can be used to characterize endemic and outbreak patterns of
shigellosis using use a suite of epidemiologic and molecular techniques. The approach is applied to
a California case study example of endemic shigellosis at the population level.
Methods:  Epidemiologic patterns were evaluated with respect to demographics, multi-drug
resistance, antimicrobial resistance genes, plasmid profiles, and pulsed-field gel electrophoresis
(PFGE) fingerprints for the 43 Shigella isolates obtained by the Monterey region health departments
over the two year period from 2004-2005.
Results: The traditional epidemiologic as well as molecular epidemiologic findings were consistent
with endemic as compared to outbreak shigellosis in this population. A steady low level of cases
was observed throughout the study period and high diversity was observed among strains. In
contrast to most studies in developed countries, the predominant species was Shigella flexneri (51%)
followed closely by S. sonnei (49%). Over 95% of Shigella isolates were fully resistant to three or
more antimicrobial drug subclasses, and 38% of isolates were resistant to five or more subclasses.
More than half of Shigella strains tested carried the tetB, catA, or blaTEM genes for antimicrobial
resistance to tetracycline, chloramphenicol, and ampicillin, respectively.
Conclusion: This study shows how epidemiologic patterns at the host and bacterial population
levels can be used to investigate endemic as compared to outbreak patterns of shigellosis in a
community. Information gathered as part of such investigations will be instrumental in identifying
emerging antimicrobial resistance, for developing treatment guidelines appropriate for that
community, and to provide baseline data with which to compare outbreak strains in the future.
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Background
Shigellosis, commonly known as acute bacillary dysen-
tery, is a global human health problem, with over 165
million cases and 1 million deaths occurring each year [1].
Shigella sonnei has been reported as the most prevalent
endemic species in developed countries, S. flexneri as the
most prevalent endemic species in developing countries,
and S. dysenteriae is known to cause sporadic outbreaks
and epidemics worldwide [1-5]. In the United States, an
estimated 450,000 people are infected each year, with
most clinical cases occurring in children [1,5,6].
Although shigellosis is generally a self-limiting disease,
antimicrobial treatment can reduce the average duration
of symptoms as well as reducing the period of Shigella
excretion after symptoms subside [7,8]. As a result of anti-
microbial use over time, Shigella isolates have developed
resistance to many commonly used antimicrobial drugs,
and mobile genetic elements including R plasmids, trans-
posons, integrons and genomic islands on the bacterial
genome can help disseminate resistance determinants
[5,9-11]. Recent reports have determined the molecular
basis of multidrug-resistance (MDR) phenotypes of Shig-
ella spp. in Australia [12], Brazil [10], China [13], India
[14], Ireland [15], Japan [16], and Korea [17]. Drug resist-
ance patterns are influenced by many factors including
geographic location, year in which the isolate was
obtained, class of antimicrobial agent, pressure exerted by
antimicrobial use, and isolate source [8,11].
Local knowledge of antimicrobial resistance patterns is
valuable as a guide to therapy, as an epidemiologic typing
method, and as an indicator of disseminating antimicro-
bial resistance in the region [11,18]. Specific PCR assays
have been developed to screen for genes associated with
virulence and antimicrobial resistance to commonly used
drugs such as ampicillin, chloramphenicol, and tetracy-
cline [5,10,19]. Plasmid profiling and chromosomal fin-
gerprinting using pulsed-field gel electrophoresis (PFGE)
are two molecular techniques that can additionally help
to characterize Shigella isolates in endemic and outbreak
situations [15,20]. Taken together, these methods provide
complementary data to compare Shigella strains in a vari-
ety of settings and communities.
The objective of this study is to use a suite of epidemio-
logic and molecular characterization techniques to
present a unified approach for characterizing endemic
and outbreak patterns of shigellosis with a California case
study example at the population level. The results
described herein include case distributions, antimicrobial
resistance testing, PCR for three antimicrobial resistance
genes, plasmid profiling, and chromosomal fingerprint-
ing to evaluate the type of drug resistance, risk factors
associated with high levels of drug resistance, and diver-
sity of strains present in a central California population
during a two year period.
Methods
Shigella strains
Clinical Shigella isolates were obtained from the Monterey
and Santa Cruz County Health Departments during 2004-
2005 under the University of California, Davis Institu-
tional Review Board Exemption Protocol 14541-1 for
working with anonymous human laboratory samples.
The bacteria were inoculated into Selenite-F enrichment
broths and onto selective agar plates for isolation and
characterization after aerobic incubation at 37°C for 24 h.
Shigella species were identified using colony morphology
and then conventional biochemical reactions including
API 20E strips (Biomerieux, France) and antisera slide
agglutination tests (BD Difco, MD). Serotype and demo-
graphic information was initially provided by the county
health departments. The Centers for Disease Control and
Prevention reference laboratory performed ipaH PCR and
subserotyping of selected Shigella isolates, and this data
was used as definitive identification in any case of discrep-
ancies.
Antimicrobial resistance testing
Drug resistance testing was performed using microdilu-
tion and disk diffusion methods as outlined by the Clini-
cal Laboratory Standards Institute [21,22], and
antimicrobial classes were defined as for the National
Antimicrobial Resistance Monitoring System (NARMS)
for enteric bacteria [23]. Sensititre Gram-negative NARMS
plates (TREK diagnostic systems, OH) were used to test
Shigella isolates for resistance to amikacin (AMK), amoxi-
cillin-clavulanic acid (AMC), ampicillin (AMX), cefoxitin
(FOX), ceftiofur (TIO), ceftriaxone (CRO), chloramphen-
icol (CHL), ciprofloxacin (CIP), gentamicin (GEN), kan-
amycin (KAN), nalidixic acid (NAL), streptomycin (STR),
sulfisoxazole (FIS), tetracycline (TET), and trimethoprim/
sulfamethoxazole (SXT). Inoculated Sensititre®  plates
were incubated overnight at 35°C and examined to deter-
mine the dilution at which bacterial growth was at least
90% inhibited. For quality control, two control strains of
Escherichia coli (ATCC 25922 and 35218) were tested as
well as the internal positive and negative controls
included in each microdilution plate.
Disk diffusion methods were used to test for azithromycin
(AZM) resistance [22]. Mueller-Hinton agar plates were
inoculated with bacteria suspended in 0.85% saline
adjusted to a turbidity equivalent to a 0.5 McFarland
standard and incubated with 15 μg azithromycin disks
(BBL, BD Diagnostics, NJ) overnight at 37°C. The area of
inhibited bacterial growth around the azithromycin disk
was measured to determine whether isolates were resist-
ant (≤ 13 mm), intermediate (14-17 mm) or sensitive (≥BMC Infectious Diseases 2009, 9:184 http://www.biomedcentral.com/1471-2334/9/184
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18 mm). Zone diameters for each isolate were measured
manually by two investigators.
PCR analysis
Selected Shigella isolates were also screened for antimicro-
bial resistance genes. Fresh colonies were suspended in
sterile water, boiled for 10 min, and centrifuged for 10
min at 1300 rpm. The supernatant was separated from the
pellet and prepared DNA was stored at -20°C. Specific
primer sets and PCR protocols targeted the tetB, catA and
blaTEM  genes associated with resistance to tetracycline,
chloramphenicol, and ampicillin, respectively [5,10].
PCR products were run on 1.3% agarose gels, stained with
ethidium bromide, and photographed under UV light on
a Gel Doc 2000 system (Bio-Rad, CA).
Plasmid profiling
Shigella isolates were screened for the presence of plasmid
DNA using standard protocols [24]. Plasmid DNA was
extracted using an alkaline lysis method with a Quantum
Prep Plasmid Miniprep Kit (Bio-rad), 14 μl of plasmid
DNA extract was added to 4 μl of tracking buffer, and the
mixture was loaded to a 0.6% agarose gel. Horizontal gel
electrophoresis was carried out in 1× Tris-acetate-EDTA
(TAE) buffer at 80 V for 1 h. The gel was stained with
ethidium bromide and visualized under ultraviolet light
(UV) using a Gel Doc 2000 system (Bio-Rad).
PFGE analysis
Chromosomal fingerprinting using PFGE was performed
on selected Shigella isolates according to Pulse Net proto-
cols [25]. Bacteria were incorporated into agarose plugs,
lysed, digested with XbaI restriction enzymes (New Eng-
land Biolabs, MA) and then run on a 1% gel at 200 V for
18 h using a CHEF Mapper system (Bio-Rad). The electro-
phoresis conditions consisted of an initial switch time of
2.16 seconds and a final switch time of 54.17 seconds. The
gel was stained with Gel Star (Cambrex Bioscience, Rock-
land, ME) and banding patterns photographed under UV
light on a Gel Doc 2000 system. Cluster analysis was per-
formed using BioNumerics software (Applied Maths Inc,
Austin TX) with comparisons made using Dice coeffi-
cients and an unweighted pair-group method with arith-
metic averages (UPGMA) [26].
Data analysis
The distributions of clinical Shigella isolates obtained dur-
ing the two year study period were grouped by month to
evaluate possible endemic versus outbreak patterns in the
community. Demographic data provided by the health
departments were analyzed with respect to the following
categorical variables: Shigella species (S. flexneri, S. sonnei),
year of isolation (2004, 2005), gender (male, female),
and age group (< 5 yrs, 5-18 yrs, > 18 yrs).
Antimicrobial resistance patterns were evaluated with
respect to Shigella species, plasmid profiles, and PFGE pat-
terns. Chi-square tests were used to compare categorical
groups, and logistic regression was additionally used to
evaluate risk factors in relation to the outcome of being
resistant to five or more antimicrobial drugs. All analyses
were performed using Stata 10.0 software (Statacorp, TX),
and P-values < 0.1 were considered significant.
Results
Demographics
During the 2004-2005 study period, 64 Shigella isolates
were obtained and the first isolate from each patient was
included in this study, resulting in a total sample size of
43 Shigella isolates. Roughly half (47%) of isolates were
collected in 2004 and 53% in 2005. The distribution of
isolates by month is shown in Figure 1, which is consist-
ent with an endemic level of shigellosis in the community.
The highest number of monthly cases was eight in July
2005 and this group was comprised of multiple species,
not a single consistent strain that would be suggestive of
an outbreak. Overall, the majority (51%) of Shigella iso-
lated were S. flexneri (serogroup B) while 49% were S. son-
nei  (serogroup D). Subserotyping of S. flexneri isolates
revealed that the most common subserotypes were 3a
(38% of isolates tested) and 1b (23%), followed by 1c and
2a (both 15%), and lastly a Y variant (-:3,4) that made up
7% of S. flexneri isolates.
Among  Shigella  patients, 60% were female, 36% were
male, and 4% were of unknown gender. With respect to
age, 29% of Shigella patients were children under 5 yrs,
44% were 5-18 yrs, 24% were over 18 yrs, and 2% were of
unknown age. Figure 2 shows the proportion of S. flexneri
and S. sonnei within each age group. Interestingly, Shigella
flexneri was isolated from patients in all age groups, in
contrast to S. sonnei that was only isolated in patients
under 18 yrs.
Antimicrobial Susceptibility
Antimicrobial drug testing was carried out on 42 Shigella
isolates divided evenly among S. flexneri and S. sonnei. Fig-
ure 3 shows the percent of S. flexneri and S. sonnei isolates
fully resistant to individual antimicrobial drugs in 2004
compared to 2005. Over 60% of S. flexneri isolates were
fully resistant to ampicillin, chloramphenicol, or tetracy-
cline in both years. Increased resistance of S. flexneri to
amoxicillin-clavulanic acid, kanamycin, streptomycin,
sulfizoxazole, and trimethoprim-sulfa was observed in
2005 compared to 2004. For S. sonnei, over 80% of iso-
lates in both years were fully resistant to streptomycin,
sulfizoxazole, tetracycline, or trimethoprim-sulfa. Less
than 50% of S. sonnei were fully resistant to ampicillin,
chloramphenicol, or kanamycin. No full drug resistanceBMC Infectious Diseases 2009, 9:184 http://www.biomedcentral.com/1471-2334/9/184
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in Shigella spp. was observed for amikacin, azithromycin,
cefoxitime, ceftiofur, ceftriaxone, ciprofloxacin, gen-
tamicin, or nalidixic acid. It is significant to note that
while none of the Shigella isolates were fully resistant to
azithromycin in this study, 86% of S. sonnei isolates
showed intermediate resistance, as did 10% of S. flexneri
isolates. Similarly for amoxicillin-clavulanic acid, 48% of
S. flexneri had an intermediate level of resistance, as did
10% S. sonnei isolates.
In addition to drug resistance to individual agents, multi-
drug resistance is also important to consider. Over 95% of
Shigella isolates in this study were resistant to three or
more antimicrobial drug subclasses as defined by NARMS
criteria and 38% of isolates were resistant to five or more.
Figure 4 shows the number of drugs that S. flexneri and S.
sonnei isolates were resistant to in 2004 and 2005. The
majority of both species were resistant to four or more
drugs in both years. The level of multi-drug resistance
increased from 2004 to 2005 for S. flexneri isolates but the
shift was less dramatic for S. sonnei.
Table 1 shows the drug resistance patterns (antibiograms)
in this study, listed from most to least common. A third of
isolates were fully resistant to streptomycin, sulfisoxazole,
tetracycline, and trimethoprim-sulfa. The next most com-
mon patterns were to ampicillin, streptomycin, sulfisoxa-
zole, tetracycline, and trimethoprim-sulfa (14% of
isolates), and then to ampicillin, choramphenicol, strep-
tomycin, sulfosoxazole, and tetracycline (10% of iso-
lates). The highest level of resistance (six antimicrobial
drugs) was detected in 7% of Shigella  isolates and
included ampicillin, chloramphenicol, streptomycin,
sulfisoxazole, tetracycline, and trimethoprim-sulfa.
Logistic regression analysis identified two risk factors sta-
tistically associated with high drug resistance as defined
by full resistance to five or more drugs. In the univariate
analysis, high drug resistance was more likely to be asso-
ciated with S. flexneri than S. sonnei (P = 0.06), and more
likely to be detected in female than male patients (P =
0.07). Age group and year of isolation were not significant
risk factors. However, when both Shigella  species and
patient gender were included in the regression model, S.
flexneri species was positively associated with high drug
resistance (P = 0.09), while gender was not significant (P
Monthly Shigella distribution in the Monterey Bay region of California, 2004-2005 Figure 1
Monthly Shigella distribution in the Monterey Bay region of California, 2004-2005.
Age distribution of Shigella species from the Monterey Bay  region of California, 2004-2005 Figure 2
Age distribution of Shigella species from the 
Monterey Bay region of California, 2004-2005. S. 
flexneri - Shigella flexneri; S. sonnei - Shigella sonnei.BMC Infectious Diseases 2009, 9:184 http://www.biomedcentral.com/1471-2334/9/184
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= 0.12). In the final model, high drug resistance was 1.2
times more likely in S. flexneri than S. sonnei, and other
risk factors were not significant.
PCR analysis
Molecular PCR amplification resulted in gels with the
415, 457, and 559 bp bands expected for genes associated
with tetracycline (tetB), chloramphenicol (catA), and
ampicillin (blaTEM) resistance, respectively. Of the 33 tet-
racycline-resistant  Shigella  tested, 100% (16/16) of S.
flexneri and 71% (12/17) of S. sonnei were positive for the
tetB gene. Of the 14 chloramphenicol resistant isolates
tested, 85% (11/13) of S. flexneri and 100% (1/1) S. sonnei
were positive for the catA gene. Of the 24 ampicillin resist-
ant Shigella tested, 21% (3/14) of S. flexneri and 44% (4/
9) of S. sonnei were positive for the blaTEM gene.
Plasmid profiling
Ten different plasmid profiles (I-X) were detected in this
study, with plasmid bands ranging from 1.5-10 kb in size.
Of the 42 isolates tested, 62% has plasmids and 38% did
not. Profile I had 1.5 and 2 kb plasmids, profile II had 1.5,
4, and 5 kb plasmids, profile III had 1.5, 2, 3, 5, 6, and 10
kb plasmids, profile IV had 2 and 2.5 kb plasmids, profile
V had 1.5, 2, and 3 kb plasmids, profile VI had 1.5 and 3
kb plasmids, profile VII had 1.4, 2, 2, 5, and 3 kb plas-
mids, profile VIII had 2 and 4.5 kb plasmids, profile IX
had 1.5, 3, and 4 kb plasmids, and profile X had 1.5, 3, 4,
and 5 kb plasmids. Table 1 shows the distribution of plas-
mid profiles and serotypes by antibiogram group, with
some antibiogram groups including multiple plasmid
profiles and serotypes.
Percent of Shigella flexneri (top) and S. sonnei (bottom) isolates fully resistant to antimicrobial drugs Figure 3
Percent of Shigella flexneri (top) and S. sonnei (bottom) isolates fully resistant to antimicrobial drugs. No full 
resistance was observed to amikacin, azithromycin, cefoxitime, ceftiofur, ceftriaxone, ciprofloxacin, gentamicin, or nalidixic 
acid.
a.
b.BMC Infectious Diseases 2009, 9:184 http://www.biomedcentral.com/1471-2334/9/184
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PFGE
Twenty-six Shigella isolates were selected for PFGE finger-
printing, with an even number of S. sonnei and S. flexneri
represented, and at least one isolate from each plasmid
profile included in the chromosomal fingerprinting anal-
ysis. The PFGE patterns after XbaI digestion are shown in
Figure 5 as dendrograms of genetic intra-species related-
ness. All PFGE patterns were unique and thus show that
there is a high level of diversity in Shigella  from the
Monterey region of California. This provides molecular
evidence to support the endemic epidemiologic pattern in
time that was observed in the initial epidemiologic evalu-
ation (Figure 1). The distribution of PFGE patterns by
antibiogram group and in relation to plasmid profile
groups and serotypes are shown in Table 1, again high-
lighting the diversity of endemic strains in this popula-
tion.
Discussion
This study shows how epidemiologic patterns at the host
and bacteria population levels can be used to investigate
endemic as compared to outbreak patterns of shigellosis
in a community. The observed pattern in time, with a
small number of cases coming in throughout the year,
along with the high diversity in molecular fingerprints of
Shigella isolates support an endemic pattern in this popu-
lation. A true spatial analysis would also be useful to eval-
uate clustering and additional risk factors for infection,
but due to patient confidentiality that data was not avail-
able. Traditional and molecular epidemiologic data gath-
ered as part of public health investigations will be
instrumental in identifying emerging antimicrobial resist-
ance, developing treatment guidelines appropriate for
communities, and providing baseline data with which to
compare future outbreak strains.
Proportion of multi-drug resistant Shigella flexneri (top) and S. sonnei (bottom) isolates from California, 2004-2005 Figure 4
Proportion of multi-drug resistant Shigella flexneri (top) and S. sonnei (bottom) isolates from California, 2004-
2005.
a.
b.BMC Infectious Diseases 2009, 9:184 http://www.biomedcentral.com/1471-2334/9/184
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There is worldwide concern about the emergence of drug
resistant strains of enteric pathogens. In this study, we
found that over 95% of Shigella  isolates from the
Monterey region of California were resistant to three or
more antimicrobial drug classes, and 38% were resistant
to five or more. This level of drug resistance is higher than
national NARMS data for the same 2004 time period,
which reported 62% resistance to three or more drug sub-
classes, and 28% resistance to five or more [23].
Another difference between this central California study
and national data is that in this study S. flexneri was the
more prevalent species, followed closely by S. sonnei. Most
studies have reported S. sonnei to be the most common
species in developed countries such as the United States,
with S. flexneri more prevalent in developing countries [1-
4,27,28]. For example, the Shiferaw [28] study reported
that S. sonnei accounted for 70% of Shigella infections in
the United States, followed by S. flexneri associated with
24% of infections. In contrast, we found that in the
Monterey region of California, S. flexneri accounted for
51% of isolates, followed by S. sonnei at 49%. Addition-
ally, we found that S. flexneri types 3a and 1b were most
common, followed by 1c, 2a, and a Y variant (-:3,4). Sub-
serotypes 2a and 3a have been reported as common in
studies from India, Thailand, and Malaysia, while subse-
rotype 1b was the predominant type in studies from
Malaysia and Peru [4]. A 2007 study [29] of adults in San
Francisco, CA conducted during 1998-1999 found a simi-
lar species distribution to our study, with S. flexneri mak-
ing up 53% of isolates and S. sonnei 46%, while a previous
1996 study [27] that included all age groups found the
more typical distribution of S. sonnei predominating over
S. flexneri at 62% versus 32%, respectively. No subserotyp-
ing data was available from the San Francisco studies.
The majority of shigellosis cases in our study occurred in
children. Approximately 40% of S. sonnei isolates were
detected in children under 5 years old, with the other 60%
of isolates detected in youth 5-18 years old. Shigella
flexneri isolates were more evenly distributed among all
age groups, with 20% of isolates occurring in children
under 5 years, 40% in youth 5-18 years, and 40% in adults
over 18 years old. Most other studies have reported the
majority of shigellosis cases in children [8,11,28,30]
though the Baer et al. study [27] in San Francisco found
the majority of cases in adults over 18 years old, along
with the risk factors of male gender, white ethnicity, and
being HIV-positive.
Ethnicity has been associated with Shigella infection in the
United States [28-31]. The Shiferaw et al. [28] study that
utilized the Foodborne Diseases Active Surveillance Net-
work (FoodNet) reported a higher incidence of S. sonnei
and S. flexneri cases among patients of black and Hispanic
ethnicity compared to white patients. That study also
noted that the highest incidences of shigellosis in the
country occurred in California and Georgia. The Kalluri et
al. [31] study of S. boydii epidemiology reported that the
majority of patients were Hispanic, and that most of the
patients who had traveled abroad in the week before
symptoms occurred had gone to Mexico. In our study we
did not have ethnicity data linked to individual cases, but
we can speculate that our results could be similarly
affected given the high percentage of Hispanics with shig-
ellosis (approximately 86% of cases from 2003-2007) in
Table 1: Shigella drug resistance patterns with associated serotypes, plasmid profiles, and PFGE fingerprint patterns from California, 
2004-2005.
Resistance pattern to the 
NARMS antimicrobial 
panel
% of isolates with 
resistance profile (no.)
Plasmid profile groups 
detected (no.)a
Species of isolates with 
plasmids (no.)
PFGE patterns
STR, FIS, TET, SXT 33% (14) II, X(3), VIII S. sonnei (4), S. flexneri III, V, VI, IX, X
AMP, STR, FIS, TET, SXT 14% (6) II(4), VI S. sonnei (5) I, IV, VII, VIII, XI, XII
AMP, CHL, STR, FIS, TET 10% (4) none none
AMP, CHL, TET 7% (3) VII S. flexneri 3a XX, XXIII, XV
AMP, CHL, STR, FIS, TET, SXT 7% (3) IV(2), V S. flexneri 3a (2), S. sonnei
TET 5% (2) I, IV S. flexneri 1b (2) XIX
AMP, CHL, FIS, TET 5% (2) IV(2) S. flexneri 2a (2) XVII
CHL, STR, FIS, TET, SXT 5% (2) V(2) S. flexneri 1c (2) XV
AMP, CHL, FIS, TET, SXT 2% (1) IV S. flexneri 2a XVIII
AMP, KAN, STR, FIS 2% (1) IV S. sonnei XIII
CHL, FIS, TET, SXT 2% (1) III S. flexneri Y var. XXIV
AMP, CHL, STR, TET 2% (1) IX S. flexneri 1b XIV
AMP, STR, FIS, SXT 2% (1) IX S. sonnei
AMC, AMP, GEN, STR, FIS 2% (1) IV S. flexneri
a Of the 42 isolates tested, 62% (n = 26) had plasmids detected while 38% (n = 16) did not.BMC Infectious Diseases 2009, 9:184 http://www.biomedcentral.com/1471-2334/9/184
Page 8 of 11
(page number not for citation purposes)
the Monterey region [32]. Many are migrant workers who
travel regularly to their countries, so it is plausible that
Shigella strains are being imported with these travelers.
The high prevalence of S. flexneri could also reflect strains
circulating among subgroups such as homosexual popula-
tions, as reported in San Francisco [29].
Treatment of shigellosis should be guided by local antimi-
crobial resistance patterns. In this central California study,
we found no full resistance to amikacin, azithromycin,
cefoxitime, ceftiofur, ceftriaxone, ciprofloxacin, gen-
tamicin, and nalidixic acid. However, significant interme-
diate resistance was observed to azithromycin in S. sonnei
isolates, and to amoxicillin-clavulanic acid in S. flexneri
isolates. The results indicate that Shigella species could
develop full resistance to these two drugs in the future,
and this should be considered when prescribing them as
empirical therapy for shigellosis. Importantly, we
Shigella sonnei (top) and S. flexneri (bottom) dendrograms showing intra-species relatedness of Pulsed Field Gel Elecrophoresis  (PFGE) fingerprints after XbaI digestion Figure 5
Shigella sonnei (top) and S. flexneri (bottom) dendrograms showing intra-species relatedness of Pulsed Field 
Gel Elecrophoresis (PFGE) fingerprints after XbaI digestion.
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observed full resistance to many drugs commonly used for
shigellosis treatment, with high resistance noted for amp-
icillin, chloramphenicol, streptomycin, sulfisoxazole, tet-
racycline, and trimethoprim-sulfa. This finding is
concerning but not surprising in light of the Sur et al. [11]
review that discusses how drug resistance has developed
in the same order in which new drugs for shigellosis treat-
ment were introduced. In the 1940's, tetracycline and then
chloramphenicol were recommended for treatment when
sulphonamides became ineffective. When further drug
resistance developed, ampicillin and co-trimoxazole were
recommended, and by the 1980's, some Shigella strains
were resistant to all of these drugs but susceptible to the
newly introduced fluoroquinolones. In recent studies,
drug resistance has been observed to fluoroquinolones as
well [33,34].
The prevalence of resistance to individual drugs in our
study was somewhat different than the NARMS data for
the 2004 year. Shigella flexneri isolates in this California
study showed comparable levels of resistance to the
national level data, but S. sonnei isolates showed more
resistance to streptomycin, sulfisoxazole, tetracycline, and
trimethoprim-sulfa and less resistance to ampicillin than
the national data. The almost 100% of S. sonnei isolates
that were fully resistant to streptomycin, sulfisoxazole, tet-
racycline, and trimethoprim-sulfa in the California study,
compared to roughly 50% of isolates found resistant in
the NARMS national report, is more consistent with what
you might expect in developing countries. The high level
of resistance in the Monterey region could have developed
in response to local use of these four antimicrobials for
shigellosis treatment, or the resistant strains might have
been imported from developing countries via the
traveling portion of the population.
Interpretation of the disk diffusion method for azithro-
mycin can be challenging due to the double zone of inhi-
bition observed for many S. sonnei isolates. Unlike most
antimicrobial disk testing, azithromycin testing of Shigella
isolates can produce an inner zone of complete growth
inhibition around the disk, surrounded by an outer zone
of reduced growth [35]. This double zone phenomenon
was observed in our study also, mainly among S.sonnei
but also among a few S.flexneri isolates. In order to make
an accurate and consistent interpretation of the zone
diameter, it is recommended to only measure the inner
zone of complete growth inhibition to interpret antimi-
crobial susceptibility [35]. Using the diameter of the outer
zone of reduced growth to interpret antimicrobial suscep-
tibility could result in underestimating the level of resist-
ance.
A variety of mechanisms may be responsible for the devel-
opment of antimicrobial resistance among Shigella
strains. Resistance may spread clonally during an out-
break situation or horizontally by plasmids, transposon-
mediated conjugation, or chromosomal gene transfer
[11]. In the current study we screened a subset of Shigella
isolates for genes associated with antimicrobial resistance
to ampicillin, chloramphenicol, and tetracycline, and
found that some but not all isolates in each antimicrobial
resistance category carried the target genes. Our results are
consistent with the Toro et al. [5] and Navia et al. [9] stud-
ies that found a heterogeneous distribution of resistance
determinants among S. flexneri and S. sonnei isolates in
Chile and Tanzania, respectively. Additional molecular
studies could be performed to further characterize drug
resistance and virulence alleles present in study isolates.
Plasmid profiling and chromosomal fingerprinting both
showed a high level of diversity among Shigella from the
Monterey Bay region of California. Of the 42 isolates char-
acterized by plasmid profiling, 62% contained plasmids
and these were distributed among ten different profiles.
Of the 26 isolates characterized by PFGE, all produced
unique chromosomal fingerprint patterns. The high level
of diversity present in the Shigella population suggests an
endemic as compared to outbreak scenario in this com-
munity, and that this suite of molecular techniques will be
useful in distinguishing outbreak from endemic strains in
California in the future. Indeed, other studies have used
plasmid profiling and PFGE to investigate the molecular
epidemiology of shigellosis in a variety of settings world-
wide [9,15,19,20].
Conclusion
This study showed how epidemiologic patterns at the host
and bacterial population levels can be used to investigate
endemic as compared to outbreak patterns of shigellosis
in a community. Information gathered as part of such
investigations will be instrumental in identifying emerg-
ing antimicrobial resistance, for developing treatment
guidelines appropriate for that community, and to pro-
vide baseline data with which to compare outbreak strains
in the future. This study confirms findings from other
parts of the world that point to a continued emergence of
multi-drug resistant strains of enteric pathogens in the
face of widespread antimicrobial use.
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